MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Seaport Therapeutics

News headline image
Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Announces Science Translational Medicine Peer-Reviewed Publication Featuring GlyphAlloTM (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele™, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics to Participate in Upcoming Investor Conferences in February and March
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Presents Data Further Validating Glyph™ Platform’s Ability to Enhance Oral Bioavailability and Expand Therapeutic Reach
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics to Present at 2025 RBC Capital Markets Healthcare Private Company Conference
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics to Present at Stifel 2025 Healthcare Conference
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics to Participate in Upcoming Investor Conferences
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Presents New Preclinical Data on SPT-320 (Glyph Agomelatine) at the Society of Biological Psychiatry (SOBP) Annual Meeting
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics to Participate in Upcoming Investor Conferences in April
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Presents New Meta-Analysis Examining Correlations Between Clinical Trial Design Factors and Placebo Response in Major Depressive Disorder Studies
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with Glyph™ Platform
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Names Lauren White as Chief Financial Officer
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Appoints Seasoned Executives to Management Team
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
From Seaport Therapeutics
Via Business Wire
News headline image
Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines
From Seaport Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story